ZYMEWORKS INC (ZYME) Stock Price, Quote, News and Overview
NASDAQ:ZYME - Nasdaq - US98985Y1082 - Common Stock - Currency: USD
ZYME Quote, Performance and Key Statistics
NASDAQ:ZYME (5/8/2025, 2:38:07 PM)
11.19
-0.15 (-1.32%)
The current stock price of ZYME is 11.19 USD. In the past month the price increased by 14.43%. In the past year, price increased by 28.72%.
ZYME Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.04 | 327.81B | ||
| AMGN | AMGEN INC | 13.21 | 147.48B | ||
| GILD | GILEAD SCIENCES INC | 12.69 | 122.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 110.29B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.39 | 59.29B | ||
| ARGX | ARGENX SE - ADR | 292.23 | 33.90B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.62B | ||
| ONC | BEIGENE LTD-ADR | 5.86 | 25.34B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.88B | ||
| NTRA | NATERA INC | N/A | 22.08B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.61B | ||
| BIIB | BIOGEN INC | 7.51 | 17.42B |
Related stock screener links
About ZYME
Company Profile
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. The company is headquartered in Middletown, Delaware and currently employs 280 full-time employees. The company went IPO on 2019-06-24. The firm is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The firm engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. The company has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. The company is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The firm has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.
Company Info
ZYMEWORKS INC
108 Patriot Drive, Suite A
Middletown DELAWARE V6H 3V9 US
CEO: Ali Tehrani
Employees: 283
Phone: 13022748744
ZYMEWORKS INC / ZYME FAQ
What is the stock price of ZYMEWORKS INC today?
The current stock price of ZYME is 11.19 USD. The price decreased by -1.32% in the last trading session.
What is the ticker symbol for ZYMEWORKS INC stock?
The exchange symbol of ZYMEWORKS INC is ZYME and it is listed on the Nasdaq exchange.
On which exchange is ZYME stock listed?
ZYME stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ZYMEWORKS INC stock?
15 analysts have analysed ZYME and the average price target is 22.84 USD. This implies a price increase of 104.08% is expected in the next year compared to the current price of 11.19. Check the ZYMEWORKS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ZYMEWORKS INC worth?
ZYMEWORKS INC (ZYME) has a market capitalization of 778.60M USD. This makes ZYME a Small Cap stock.
How many employees does ZYMEWORKS INC have?
ZYMEWORKS INC (ZYME) currently has 283 employees.
What are the support and resistance levels for ZYMEWORKS INC (ZYME) stock?
ZYMEWORKS INC (ZYME) has a support level at 10.92 and a resistance level at 12.89. Check the full technical report for a detailed analysis of ZYME support and resistance levels.
Is ZYMEWORKS INC (ZYME) expected to grow?
The Revenue of ZYMEWORKS INC (ZYME) is expected to grow by 4.31% in the next year. Check the estimates tab for more information on the ZYME EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ZYMEWORKS INC (ZYME) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ZYME, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ZYME, evaluating the profitability, health, valuation and growth aspects
- ZYMEWORKS INC (ZYME) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ZYMEWORKS INC (ZYME) Sales and EPS estimates to see what analysts future expectations are.
- ZYMEWORKS INC (ZYME) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ZYMEWORKS INC (ZYME) Insider and Institutional Ownership to learn about the owners and their transactions.
- ZYMEWORKS INC (ZYME) Stock Chart to make your own analysis
- ZYMEWORKS INC (ZYME) Latest news and press-releases to stay up to date.
Does ZYMEWORKS INC (ZYME) stock pay dividends?
ZYME does not pay a dividend.
When does ZYMEWORKS INC (ZYME) report earnings?
ZYMEWORKS INC (ZYME) will report earnings on 2025-05-08, after the market close.
What is the Price/Earnings (PE) ratio of ZYMEWORKS INC (ZYME)?
ZYMEWORKS INC (ZYME) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.39).
What is the Short Interest ratio of ZYMEWORKS INC (ZYME) stock?
The outstanding short interest for ZYMEWORKS INC (ZYME) is 9.65% of its float. Check the ownership tab for more information on the ZYME short interest.
ZYME Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to ZYME. When comparing the yearly performance of all stocks, ZYME is one of the better performing stocks in the market, outperforming 76.41% of all stocks.
ZYME Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ZYME. While ZYME seems to be doing ok healthwise, there are quite some concerns on its profitability.
ZYME Financial Highlights
Over the last trailing twelve months ZYME reported a non-GAAP Earnings per Share(EPS) of -1.39. The EPS increased by 19.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.49% | ||
| ROE | -36.22% | ||
| Debt/Equity | 0 |
ZYME Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to ZYME. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of -22.79% and a revenue growth 4.31% for ZYME